Compare · DYN vs PEPG

DYN vs PEPG

Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and PepGen Inc. (PEPG): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DYN and PEPG operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • DYN is the larger of the two at $3.00B, about 8.1x PEPG ($370.4M).
  • Over the past year, DYN is down 20.3% and PEPG is down 22.8% - DYN leads by 2.5 points.
  • DYN has been more active in the news (13 items in the past 4 weeks vs 12 for PEPG).
  • DYN has more recent analyst coverage (24 ratings vs 6 for PEPG).
PerformanceDYN-20.30%PEPG-22.84%
2025-11-20+0.00%2026-11-19
MetricDYNPEPG
Company
Dyne Therapeutics Inc.
PepGen Inc.
Price
-
-
Market cap
$3.00B
$370.4M
1M return
-0.34%
+44.14%
1Y return
-20.30%
-22.84%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2020
2022
News (4w)
13
12
Recent ratings
24
6
DYN

Dyne Therapeutics Inc.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.

PEPG

PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Latest DYN

Latest PEPG